Compare ABR & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | NUVB |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | 653 | 298 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | ABR | NUVB |
|---|---|---|
| Price | $5.74 | $4.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $9.90 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 5.6M | 4.2M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | $9.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.40 | $1.57 |
| 52 Week High | $12.58 | $9.75 |
| Indicator | ABR | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 52.73 |
| Support Level | N/A | $4.07 |
| Resistance Level | $8.08 | $5.23 |
| Average True Range (ATR) | 0.34 | 0.25 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 18.82 | 71.35 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.